Table 3 Treatment-related common adverse events in this meta-analysis.

From: Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis

Adverse events

All grades

Grade ≥ 3

RR (95% CI)

P

RR (95% CI)

P

Anemia

0.35 (0.27, 0.46)

≤0.001

0.34 (0.23, 0.49)

≤0.001

Alopecia

0.12 (0.08, 0.19)

≤0.001

0.29 (0.11, 0.76)

0.012

Arthralgia

1.05 (0.80, 1.38)

0.728

1.49 (0.79, 2.84)

0.219

Neutropenia

0.16 (0.11, 0.25)

≤0.001

0.22 (0.14, 0.34)

≤0.001

Diarrhea

0.82 (0.70, 0.97)

0.020

0.97 (0.68, 1.38)

0.859

Dyspnea

0.99 (0.84, 1.17)

0.943

0.95 (0.65, 1.38)

0.790

Stomatitis

0.31 (0.20, 0.48)

≤0.001

0.31 (0.14, 0.70)

0.005

Nausea

0.60 (0.49, 0.73)

≤0.001

0.76 (0.54, 1.05)

0.098

Pyrexia

1.23 (1.03, 1.48)

0.024

0.92 (0.40, 2.10)

0.844

Asthenia

0.69 (0.60, 0.79)

≤0.001

0.55 (0.39, 0.79)

≤0.001

Rash

1.56 (1.26, 1.92)

≤0.001

1.31 (0.80, 2.15)

0.277

Neuropathy

0.39 (0.26, 0.60)

≤0.001

0.81 (0.44, 1.49)

0.504

Fatigue

0.77 (0.70, 0.85)

≤0.001

0.55 (0.42, 0.72)

≤0.001

Vomit

0.61 (0.45, 0.81)

≤0.001

0.66 (0.44, 0.98)

0.040

Constipation

0.63 (0.48, 0.83)

≤0.001

0.78 (0.32, 1.88)

0.575

Pneumonitis

2.44 (1.23, 4.87)

0.011

1.67 (0.94, 2.96)

0.080

Pruritus

3.46 (2.67, 4.49)

≤0.001

0.90 (0.27, 3.00)

0.869

Mucosal Inflammation

0.29 (0.18, 0.44)

≤0.001

0.34 (0.18, 0.66)

0.002

Decreased Appetite

0.19 (0.08, 0.42)

≤0.001

0.76 (0.49, 1.19)

0.228

Decreased Neutrophil Count

0.17 (0.09, 0.22)

≤0.001

0.17 (0.09, 0.35)

≤0.001

Decreased White-Cell Count

0.19 (0.08, 0.42)

≤0.001

0.19 (0.08, 0.49)

≤0.001